DOI: https://doi.org/10.22141/2224-0721.5.53.2013.84505

Lipids, Inflammation and Pathology of the Human: Role of Peroxisome Prolifera tor-Activated Receptors (Literature Review)

M.S. Rasin

Abstract


Chronic systemic indolent uncontrolled inflammation is the basis for the development of many chronic diseases, including atherosclerosis and its ischemic complications, hypertension, type 2 diabetes mellitus, hepatosteatosis and many others. Lipids (fatty acids and their derivatives — eicosanoids) are the mediators of the chronic inflammation. Excessive accumulation of metabolically active adipose tissue is also a source of chronic inflammation due to involvement in it of macrophages, which secrete inflammatory cytokines, and their activation. The peroxisome proliferator-activated receptors (PPAR), nuclear transcription factors (NTF) stand at the crossroads between lipids and inflammation, since lipids, stimulating chronic inflammation, are ligands — PPAR activators. PPAR — the main anti-inflammatory factors, inhibiting the activity of proinflammatory NTF: activating protein-1 and NFkB. Studying biology of PPAR and their clinical application — the way to true pathogenetic treatment of many chronic diseases.


Keywords


lipids; inflammation; receptors; peroxisome proliferator-activated receptors

References


Calder P.C. ω-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases // Am. J. Clin. Nutr. — 2006. — Vol. 83. — P. 1505-1519.

Wahli W., Michlik L. PPARs at the crossroads of lipid signaling and inflammation // Trends in Endocrinology and Metabolism. — 2012. — Vol. 23, № 7. — P. 351-363.

Dasu M.R. et al. Toll-like receptors and diabetes: a therapeutic perspective // Clin. Sci. — 2012. — Vol. 122. — P. 203-214.

Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation // Ann. Rev. Pharmacol. Toxicol. — 2009. — Vol. 49. — P. 123-150.

Mandard S., Patsouris D. Nuclear Control of the Inflammatory Response in Mammals by Peroxisome Proliferator-Activated Receptors // PPAR Research. — 2013. — Vol. 2013. Article ID 613864, http://dx.doi.org/10.1155/2013/613864

Ferre P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity // Diabetes. — 2004. — Vol. 53. — P. 43-50.

Forman B.M., Tontonoz P., Chen J. et al. 15-Deoxy-12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ // Cell. — 1995. — Vol. 83. — P. 803-812.

Rakhshandehroo M., Knoch B., Muller M. et al. Peroxisome proliferator-activated receptor alpha target genes // PPAR Research. — 2010. ID 612089. doi:10.1155/2010/612089.

Ehrenborg E., Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor δ // Pharmacological Reviews. — 2009. — Vol. 61, № 3. — P. 373-393.

Oliver W.R., Shenk J.L., Snaith M.R. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport // Proc. Natl Acad. Sci. USA. — 2001. — Vol. 24, № 98(9). — P. 5306-5311.

Bishop-Bailey D., Bystrom O. Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation // Pharmacology and Therapeutics. — 2009. — Vol. 124. — P. 141-150.

George J. Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis // Nature Clinical Practice Cardiovascular Medicine. — 2008. — Vol. 5, № 9. — P. 531-540.

Maeda N., Takahashi M., Funahashi T. et al. PPAR-gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein // Diabetes. — 2001. — Vol. 50. — P. 2094-2099.

Memon R.A., Tecott L.H., Nonogaki K. Up-regulation of peroxisome proliferator-activated receptors (PPARα and PPARγ) messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-responsive adipose tissue-specific genes in the liver of obese diabetic mice // Endocrinology. — 2000. — Vol. 141. — P. 4021-4031.

Way J.M., Harrington W.W., Brown K.K. et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues // Endocrinology. — 2001. — Vol. 142. — P. 1269-1277.

Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism // Endocr. Rev. — 1999. — Vol. 20. — P. 649-688.

Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation // Ann. Rev. Pharmacol. Toxicol. — 2009. — Vol. 49. — P. 123-150.

Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors // Nature. — 2008. — Vol. 454. — P. 470-474.

Varga T. et al. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation // Biochim. Biophys. Acta. — 2011. — Vol. 1812. — P. 1007-1022.

Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms // Trends Immunol. — 2007. — Vol. 28. — P. 551-558.

Stienstra R. et al. The interleukin-1 receptor antagonist is a direct target gene of PPAR-alpha in liver // J. Hepatol. — 2007. — Vol. 46. — P. 869-887.

Leuenberger N. et al. Sumoylated PPAR-alpha mediates sex- specific gene repression and protects the liver from estrogen-induced toxicity in mice // J. Clin. Invest. — 2009. — Vol. 119. — P. 3138-3148.

Narala V.R. et al. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist // J. Biol. Chem. — 2010. — Vol. 285. — P. 22067-22074.

Okopień B. et al. Monocyte release of tumor necrosis factor-alpha and interleukin-1 beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates // J. Cardiovasc. Pharmacol. — 2005. — Vol. 46 (3). — P. 377-386.

Poulsen L.L. et al. PPARs: fatty acid sensors controlling metabolism // Cell. Dev. Biol. — 2012. http://dx.doi.org/10.1016/j. semcdb.2012.01.003.

Stienstra R., Mandard S., Tan N.S. et al. The Interleukin-1 receptor antagonist is a direct target gene of PPARα in liver // J. Hepatology. — 2007. — Vol. 46. — P. 869-877.

Bougarne N. et al. PPAR-alpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB // Proc. Natl Acad. Sci. U.S.A. — 2009. — Vol. 106. — P. 7397-7402.

Kang K., Reilly S.M., Karabacak V. et al. Adipocyte-derived Th2 cytokines and myeloid PPARδ regulate macrophage polarization and insulin sensitivity // Cell. Metabolism. — 2008. — Vol. 7 (6). — P. 485-495.

Coll T., Barroso E., Alvarez-Guardia D. The role of peroxisome proliferator-activated receptor β/δ on the inflammatory basis of metabolic disease // PPAR Res. — 2010. — Vol. 2010. — P. 368-467.

Кайдашев И.П. NF-kB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза / И.П. Кайдашев // Международный эндокринологический журнал. — 2011. — Т. 3(35). — С. 35-40.

Кайдашев І.П., Расін О.М., Микитюк М.В., Ра-сін М.С. Аторвастатин та розиглітазон індукують апоптоз моноцитів/макрофагів крові: роль поліморфізму гена PPARγ // Ліки. — 2007. — № 4. — С. 55-58.

Расін О.М. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPAR-γ / О.М. Расін, І.П. Кайдашев, М.С. Расін // Міжнародний ендокринологічний журнал. — 2007. — № 6(12). — С. 71-76.

Расин А.М., Кайдашев И.П., Расин М.С. Пероксисом пролифератор-активирующие рецепторы и их роль в системном воспалении, атерогенезе, артериальной гипертензии и хроническом обструктивном заболевании легких (обзор литературы) // Український терапевтичний журнал. — 2006. — № 2. — С. 100-108.

Takata Y., Liu J. PPAR-delta mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis // Proc. Natl Acad. Sci. U. S. A. — 2008. — Vol. 105(11). — P. 4277-4282.

Oshima K., Mogi M., Horiuchi M. Role of peroxisome proliferator-activated receptor-γ in vascular inflammation // Journal of International Vascular Medicine. — 2012. — Internet resource.

Hirabara S.M. et al. Molecular targets related to inflammation and insulin resistance and potential interventions // Journal of Biomedicine and Biotechnology. — Internet resource. Vol. 2012 (2012).

Sample R.K., Krishna V., Chatterjee K., O’Rahilly S. PPARγ and human metabolic disease // J. Clin. Invest. — 2006. — Vol. 116(3). — P. 581-589.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта